Medindia
About ▼ Careers Internship MedBlog Contact us
English (US) ▼
Medindia
LOGIN REGISTER
Advertisement

Anpac Bio Presenting 'Unprecedented' Cerebral Cancer Liquid Biopsy Research Results at ASCO 2019

Thursday, May 30, 2019 General News
Advertisement
The American Society of Clinical Oncology #ASCO has published/posted Anpac Bio’s Non-Small Cell Lung Cancer early detection screening research study Abstract, “A novel biophysical based marker with multilevel, multiparameter expression for early stage cancer detection.” The Abstract demonstrates Anpac Bio’s “Cancer Differentiation Analysis” liquid biopsy technology identified Stage I NSCLC with significant accuracy-achieving 85% sensitivity and 93% specificity from simple, standard blood tests.
Advertisement

Anpac Bio-Medical Science Company will be at Booth #21103 at the American Society of Clinical Oncology #ASCO Annual Meeting in Chicago, IL, May 31-June 4, 2019. The #AnpacBio team will share information regarding its breakthrough, "Cancer Differentiation Analysis" liquid biopsy technology research, demonstrating CDA identifies 28+ early-stage cancers with a single, standard blood sample. Anpac Bio will also share cerebral cancer research results at a Poster Session on Sunday, June 2, 2019.
Advertisement

International life sciences leader Anpac Bio-Medical Science Company has developed breakthrough, proprietary, "Cancer Differentiation Analysis" liquid biopsy technology that effectively reinvents cancer screening and early detection. Anpac Bio's proprietary CDA medical devices analyze simple, standard, non-invasive "Blood Biopsies" - resulting in measurably greater early cancer detection sensitivity and specificity, with no harmful side effects in patients. The proven results of 120,000 cases to date demonstrate CDA's research validity achieving an average sensitivity and specificity rate range of 75%-90% for 28+ different types of cancer -- often identifying the type and location of threatening, diseased cancer cells before they form into tumors. Fully-commercialized and the only company earning liquid biopsy revenue globally, Anpac Bio has filed 250+ CDA-related Patents; 101+ issued to date worldwide. For more information: AnpacBio.com. (PRNewsFoto/Anpac Bio-Medical Science Co.)

Sponsored Post and Backlink Submission


Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors
V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...
Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome
Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...
World IBS Day - April 19th: Raising Awareness for Everyone with IBS
Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...
Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short
More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...
Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer
The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close